Generate Biomedicines' lead asthma candidate GB0895, an anti-TSLP molecule, entered phase three trials in December of last year and is enrolling across 400 different sites.
GENB · Generate Biomedicines, Inc.
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consist of its cash, cash equivalents and marketable securities on hand at September 30, 2026, together with the $30.0 million upfront payment received from Zealand in October 2026 in connection with the Zealand collaboration, it expects to have sufficient cash to fund its current operating plan into the first half of 2028.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 68%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Feb 2026 to Nov 2026
The closing range uses available history since Feb 27, 2026; less than a full year is stored.
Up next
Latest documents
Generate Biomedicines reported a $87.7 million net loss and $404.2 million in cash, cash equivalents, and marketable securities as of Sept. 30, 2026; it believes resources including $30.0 million from Zealand will fund its current operating plan into the first half of 2028.
Generate Biomedicines reported a $216.6 million net loss and $204.4 million in research and development expenses for the nine months ended September 30, 2026; cash, cash equivalents and marketable securities totaled $404.2 million as of September 30, 2026.
Generate Biomedicines said Solaria entered phase three for severe asthma; early data suggested dosing every six months and key biomarker reductions at least as well as tezapelumab.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| CAR signaling domain | 70% | early preclinical research | — |
| Cash, cash equivalents, and marketable securities | $457.4M | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GENB
this stock
Generate Biomedicines, Inc.
|
$1.23B | — | — | — | 7.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 16
Generate Biomedicines' lead asthma candidate GB0895, an anti-TSLP molecule, entered phase three trials in December of last year and is enrolling across 400 different sites.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GENB | -21.0% | -23.1% | -20.3% | -34.0% | — |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -12.4% | -13.9% | -11.1% | -25.3% | — |